Emerging Treatment Considerations in HCC: An Expert Case-Based Discussion

EP. 1: Patient Profile 1: Resection for Early/Intermediate Stage HCC

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

EP. 2: Early-Stage HCC: Role of Adjuvant Therapy

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

EP. 3: Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

EP. 4: Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

EP. 5: Selection and Use of Systemic Therapy in Intermediate Stage HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

EP. 6: Management of HCC: Advances in Biomarkers and Screening

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

EP. 7: Patient Profile 2: Frontline Therapy for Advanced HCC

ByTanios S. Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

EP. 8: HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

EP. 9: Real-World Selection of Frontline Combination Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

EP. 10: Role of Hepatitis Status in Selecting Therapy for HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

EP. 11: Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

EP. 12: Frontline Therapy for Advanced HCC: Novel Combination Strategies

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

EP. 13: Patient Profile 3: Second-Line Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.